Vascular Risk Factors in Alzheimer's Disease

Migration, Crosslink

📖

Vascular Risk Factors in Alzheimer's Disease

active

wiki page Created: 2026-04-02T07:19:55 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-vascular-risk-factors-al

📖 Wiki Page

mechanism2764 wordssynced 2026-04-02

Vascular Risk Factors in Alzheimer's Disease

Overview

Vascular risk factors play a critical role in the pathogenesis of Alzheimer's disease (AD), with growing evidence demonstrating that cerebrovascular dysfunction contributes significantly to disease initiation and progression. The interaction between vascular pathology and traditional AD hallmarks—amyloid-beta (Aβ) plaques and tau neurofibrillary tangles—has led to the recognition of Alzheimer's disease as a mixed pathology entity in many patients. This page provides comprehensive coverage of major vascular risk factors, their mechanisms, clinical evidence, and therapeutic implications.

Introduction

Alzheimer's disease and cerebrovascular disease frequently coexist, with vascular pathology accounting for a substantial portion of cognitive impairment burden in aging populations. The concept of "vascular cognitive impairment and dementia" (VCID) highlights the importance of cerebrovascular health in AD etiology[@iadecola2013]. Epidemiological studies indicate that approximately 30-40% of dementia cases demonstrate mixed AD and cerebrovascular pathology at autopsy[@toledo2013]. This overlap has significant implications for prevention strategies, diagnostic approaches, and therapeutic interventions.

...

Vascular Risk Factors in Alzheimer's Disease

Overview

Vascular risk factors play a critical role in the pathogenesis of Alzheimer's disease (AD), with growing evidence demonstrating that cerebrovascular dysfunction contributes significantly to disease initiation and progression. The interaction between vascular pathology and traditional AD hallmarks—amyloid-beta (Aβ) plaques and tau neurofibrillary tangles—has led to the recognition of Alzheimer's disease as a mixed pathology entity in many patients. This page provides comprehensive coverage of major vascular risk factors, their mechanisms, clinical evidence, and therapeutic implications.

Introduction

Alzheimer's disease and cerebrovascular disease frequently coexist, with vascular pathology accounting for a substantial portion of cognitive impairment burden in aging populations. The concept of "vascular cognitive impairment and dementia" (VCID) highlights the importance of cerebrovascular health in AD etiology[@iadecola2013]. Epidemiological studies indicate that approximately 30-40% of dementia cases demonstrate mixed AD and cerebrovascular pathology at autopsy[@toledo2013]. This overlap has significant implications for prevention strategies, diagnostic approaches, and therapeutic interventions.

The vascular hypothesis of AD proposes that cerebral vascular dysfunction initiates or accelerates neurodegenerative processes through multiple pathways, including reduced clearance of Aβ, blood-brain barrier (BBB) disruption, chronic hypoperfusion, and neuroinflammation[@sweeney2019]. Understanding these mechanisms provides opportunities for intervention at multiple points in the disease continuum.

Major Vascular Risk Factors

Hypertension

Hypertension represents one of the most well-established vascular risk factors for AD, with extensive epidemiological and clinical evidence supporting its role in disease pathogenesis. Midlife hypertension (typically defined as occurring between ages 40-64) is associated with a 2-3-fold increased risk of developing AD in later life[@walker2020]. The relationship appears to be nonlinear, with both excessively high and low blood pressure in late life showing associations with cognitive decline.

Epidemiological Evidence:
The Framingham Heart Study and other large cohort studies have consistently demonstrated that elevated blood pressure in midlife predicts incident dementia[@pase2022]. The SPRINT-MIND trial provided important insights into the relationship between intensive blood pressure control and cognitive outcomes, showing that targeting systolic blood pressure to <120 mmHg reduced the risk of mild cognitive impairment (MCI)[@sprint2019].

Mechanisms:
Hypertension contributes to AD pathogenesis through multiple interconnected pathways:

Chronic Cerebral Hypoperfusion: Sustained elevated blood pressure leads to adaptive changes in cerebral vasculature, including arteriolosclerosis and lipohyalinosis, which reduce cerebral blood flow. Chronic hypoperfusion activates a cascade of events including white matter injury, oligodendrocyte dysfunction, and axonal damage[@iadecola2019].

Blood-Brain Barrier Disruption: Hypertension compromises endothelial tight junctions and pericyte function, increasing BBB permeability. This allows plasma proteins and potentially toxic substances to enter the brain parenchyma, triggering neuroinflammatory responses[@montagne2020].

Impaired Aβ Clearance: Cerebral vasculature plays a critical role in clearing Aβ through multiple pathways, including receptor-mediated transport across the BBB. Hypertension disrupts these clearance mechanisms, promoting Aβ accumulation[@van2021].

Microvascular Rarefaction: Chronic hypertension leads to loss of cerebral microvasculature, reducing capillary density and compromising cerebral perfusion reserve[@toth2020].

Promotion of Tau Pathology: Hypertension may accelerate tau phosphorylation and spread through vascular-mediated mechanisms, including impaired cerebrospinal fluid (CSF) circulation and altered tau clearance[@kauersantanna2023].

Diabetes Mellitus Type 2

Type 2 diabetes mellitus (T2DM) approximately doubles the risk of developing AD, making it one of the most significant modifiable risk factors. The relationship between T2DM and AD has been termed "type 3 diabetes" by some researchers, reflecting the brain's insulin resistance state in AD[@monte2020].

Epidemiological Evidence:
Multiple large prospective studies, including the Framingham Offspring Study and the Maastricht Aging Study, have demonstrated that individuals with T2DM have a 1.5-2.5 fold increased risk of developing AD[@vemuri2022]. The Honolulu-Asia Aging Study specifically linked midlife diabetes to increased AD pathology at autopsy[@peila2021].

Mechanisms:

Central Insulin Resistance: The brain relies on insulin for multiple functions, including synaptic plasticity, memory formation, and Aβ clearance. Insulin resistance impairs these processes and promotes Aβ aggregation[@arnold2023].

Advanced Glycation End Products (AGEs): Hyperglycemia leads to formation of AGEs, which accumulate in AD brain tissue. AGEs bind to their receptor (RAGE) on neurons and glia, activating pro-inflammatory and oxidative stress pathways[@srikanth2021].

Microvascular Dysfunction: Diabetes causes cerebral microvascular rarefaction, endothelial dysfunction, and impaired autoregulation, reducing cerebral perfusion[@biessels2022].

Tau Hyperphosphorylation: Insulin signaling interferes with tau phosphorylation through dysregulation of GSK-3β and other kinases, promoting neurofibrillary tangle formation[@el2024].

Impaired Aβ Clearance: Insulin-degrading enzyme (IDE), which degrades both insulin and Aβ, becomes saturated in T2DM, reducing Aβ clearance capacity[@qiu2020].

Hypercholesterolemia

Elevated cholesterol levels, particularly in midlife, are associated with increased AD risk. The relationship between cholesterol and AD is complex, with both high and low late-life cholesterol showing associations with cognitive decline[@solomon2022].

Epidemiological Evidence:
The CAIDE study demonstrated that elevated midlife serum total cholesterol (≥6.5 mmol/L) was associated with a 2.8-fold increased risk of AD[@kivipelto2021]. However, some studies have shown that low late-life cholesterol is associated with cognitive decline, potentially reflecting preclinical disease rather than a protective effect.

Mechanisms:

Amyloid Processing: Cholesterol modulates amyloid precursor protein (APP) processing and Aβ production. High cholesterol increases Aβ generation through effects on γ-secretase activity and lipid raft formation[@paolo2023].

Aβ Efflux Transport: High-density lipoprotein (HDL) and its apolipoproteins facilitate Aβ efflux from the brain. Decreased HDL levels impair this clearance pathway[@michaelson2020].

Vascular Effects: Hypercholesterolemia accelerates atherosclerosis, including cerebral large and small vessel disease, reducing cerebral perfusion[@van2021a].

Statin Effects: Statin use has been associated with reduced AD risk in some observational studies, though randomized controlled trials have shown mixed results[@chu2022].

Smoking

Smoking is a significant modifiable risk factor for AD, with current smokers showing approximately 30-50% increased risk compared to never smokers[@zhong2020]. The relationship is dose-dependent, with heavier smoking associated with greater risk.

Mechanisms:

Oxidative Stress: Cigarette smoke contains numerous pro-oxidant compounds that generate reactive oxygen species (ROS), promoting neuronal oxidative damage[@kumar2021].

Atherosclerosis: Smoking accelerates systemic and cerebral atherosclerosis, compromising cerebral blood flow[@durazzo2022].

Nicotinic Receptor Effects: While nicotine may have transient cognitive effects, chronic exposure leads to receptor downregulation and may paradoxically impair cognition[@picciotto2020].

Neuroinflammation: Smoking activates glial cells and promotes chronic neuroinflammation, a key contributor to neurodegeneration[@sturman2020].

DNA Damage: Tobacco smoke contains mutagenic compounds that may contribute to neuronal dysfunction and death[@soman2023].

Atrial Fibrillation

Atrial fibrillation (AF) is associated with a 1.4-2.0 fold increased risk of all-cause dementia, including AD[@singhmanoux2021]. The relationship appears independent of stroke occurrence, suggesting multiple pathogenic mechanisms.

Epidemiological Evidence:
Large cohort studies including the Framingham Heart Study have demonstrated that AF is associated with accelerated cognitive decline and increased dementia risk, even in the absence of clinical stroke[@dagres2022].

Mechanisms:

Cerebral Hypoperfusion: Irregular heart rhythm reduces cardiac output, leading to chronic cerebral hypoperfusion[@liao2020].

Cardioembolic Events: AF increases risk of subclinical cerebral microinfarcts, which may accumulate over time[@kwok2021].

Biomarker Elevation: NT-proBNP and other cardiac biomarkers associated with AF correlate with cognitive impairment[@jani2022].

Anticoagulation Effects: Both under-anticoagulation (increasing stroke risk) and over-anticoagulation (increasing hemorrhage risk) may contribute to cognitive outcomes[@baek2023].

Cerebral Small Vessel Disease

Cerebral small vessel disease (CSVD) encompasses a group of pathological processes affecting the small vessels of the brain, including arterioles, capillaries, and venules. CSVD is highly prevalent in AD and contributes to cognitive impairment through both independent effects and interaction with AD pathology[@pantoni2020].

White Matter Hyperintensities

White matter hyperintensities (WMHs), visible as hyperintense regions on T2-weighted MRI, represent areas of demyelination, axonal loss, and gliosis resulting from chronic ischemia.

Mermaid diagram (expand to render)

Clinical Significance:
WMH burden correlates with executive dysfunction, processing speed impairment, and gait disturbances. In AD, WMHs accelerate cognitive decline and are associated with faster progression["@prins2022"].

Management:
Blood pressure control, antiplatelet therapy in select cases, and lifestyle modifications may slow WMH progression["@wardlaw2023"].

Lacunes

Lacunes are small (3-15 mm) subcortical infarcts resulting from occlusion of penetrating arterioles. They are associated with executive dysfunction and contribute to the vascular cognitive impairment phenotype[@vermeer2021].

Cerebral Microbleeds

Cerebral microbleeds (CMBs), detected on susceptibility-weighted imaging, represent small hemorrhages from compromised cerebral vessels. Their prevalence increases with age and is higher in AD, particularly in association with cerebral amyloid angiopathy (CAA)[@greenberg2020].

Vascular Cognitive Impairment

Vascular cognitive impairment (VCI) encompasses the entire spectrum of cognitive disorders caused by cerebrovascular disease, from mild cognitive impairment to dementia. The term "vascular dementia" is now reserved for cases where vascular pathology is the predominant cause[@skrobot2020].

Diagnostic Criteria

Current diagnostic frameworks emphasize:

Presence of cognitive impairment
Evidence of cerebrovascular disease (clinical or neuroimaging)
Relationship between vascular disease and cognitive deficits

Subtypes

Multi-infarct Dementia: Multiple cortical infarcts causing stepwise cognitive decline

Strategic Infarct Dementia: Single infarcts in critical cognitive regions

Binswanger's Disease: Subcortical white matter disease

Mixed Dementia: AD pathology combined with vascular pathology

Mixed Dementia

Mixed dementia, defined as the presence of AD pathology alongside other neurodegenerative or vascular pathologies, is more common than "pure" AD in population-based autopsy studies[@boyle2023].

Prevalence

| Pathology Combination | Prevalence |
|----------------------|------------|
| AD + Cerebrovascular disease | 30-40% |
| AD + Lewy bodies | 10-30% |
| AD + TDP-43 | 20-50% |
| AD + Hippocampal sclerosis | 10-20% |

Clinical Implications

Mixed dementia presents challenges for diagnosis and treatment:

Patients may not meet criteria for "pure" AD
Treatment response may differ from pure AD
Vascular risk modification may be particularly beneficial

Metabolic Syndrome and Lifestyle Factors

Obesity

Midlife obesity (BMI ≥30 kg/m²) is associated with approximately 1.5-2.0 fold increased AD risk. The relationship is mediated through multiple pathways including insulin resistance, inflammation, and vascular disease[@albanese2021].

Sedentary Lifestyle

Physical inactivity is a major modifiable risk factor, with regular exercise showing benefits for cognitive function and potentially reducing AD risk through multiple mechanisms including improved cerebral blood flow, reduced inflammation, and enhanced neuroplasticity[@kramer2022].

Diet

The Mediterranean diet and DASH diet have been associated with reduced cognitive decline and lower AD risk. These dietary patterns emphasize vegetables, fruits, whole grains, and lean proteins while limiting processed foods and saturated fats[@van2023].

Blood-Brain Barrier Dysfunction

Blood-brain barrier dysfunction is increasingly recognized as an early event in AD pathogenesis, potentially preceding clinical symptoms and amyloid deposition[@sweeney2022].

| Factor | Effect on BBB |
|--------|---------------|
| Pericyte loss | Impaired Aβ clearance across BBB |
| Endothelial dysfunction | Reduced transport capacity |
| Tight junction disruption | Increased permeability |
| Matrix metalloproteinases | Degradation of basement membrane |

Biomarkers

Vascular contributions to AD can be assessed through various biomarkers:

| Marker | Imaging | Clinical Significance |
|--------|---------|----------------------|
| White matter hyperintensities | MRI T2/FLAIR | CSVD burden |
| Lacunes | MRI | Recent and old infarcts |
| Cerebral microbleeds | MRI SWI | Hemorrhagic lesions |
| Perivascular spaces | MRI T1 | Glymphatic dysfunction |
| Aβ42/40 ratio | CSF/Plasma | AD pathology |
| Neurofilament light | CSF/Plasma | Axonal injury |
| VILIP-1 | CSF | Neuronal injury |

Therapeutic Implications

Vascular Risk Management

Blood Pressure Control: Target systolic BP <130 mmHg in most adults, with individualization based on comorbidities[@american2023].

Lipid Management: Statin therapy for appropriate patients, targeting LDL-C levels based on cardiovascular risk[@grundy2024].

Anticoagulation: For AF patients, direct oral anticoagulants (DOACs) are preferred over warfarin for most patients[@hindricks2024].

Diabetes Management: Tight glycemic control may reduce microvascular complications, though evidence for cognitive benefits is mixed[@cryer2023].

Cerebral Perfusion Enhancement

Vasodilators: Investigational agents targeting cerebral vasculature
Exercise: Promotes angiogenesis and improves cerebral blood flow
PDE5 Inhibitors: Under investigation for enhancing cerebral perfusion

Future Directions

Several novel therapeutic approaches are under investigation:

Anti-amyloid therapies with vascular comorbidity considerations
Small molecules targeting cerebral vasculature
Gene therapy approaches for vascular growth factors

Cross-Links

[Blood-Brain Barrier Breakdown in AD](/mechanisms/bbb-breakdown-ad)
[Vascular Dementia Pathway](/mechanisms/vascular-dementia-pathway)
[Cerebrovascular Disease in Neurodegeneration](/mechanisms/cerebrovascular-disease)
[Insulin Resistance in AD](/mechanisms/insulin-resistance-ad)
[Metabolic Dysfunction in AD](/mechanisms/metabolic-dysfunction-alzheimers)
[Neurovascular Unit Dysfunction](/mechanisms/neurovascular-unit-dysfunction)
[White Matter Lesion Pathway](/mechanisms/white-matter-lesion-pathway)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Unknown (n.d.)

[Iadecola, C., The pathobiology of vascular dementia (2013)](https://doi.org/10.1016/j.neuron.2013.10.008)

[Toledo et al., Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases (2013)](https://doi.org/10.1093/brain/artt165)

[Sweeney et al., Vascular dysfunction—The disregarded partner of Alzheimer's disease (2019)](https://doi.org/10.1016/j.jalz.2018.07.222)

[Walker et al., Midlife and late-life vascular risk factors and cortical thickness (2020)](https://doi.org/10.1212/WNL.0000000000010469)

[Pase et al., Association of midlife blood pressure profiles with dementia risk (2022)](https://doi.org/10.1212/WNL.0000000000200527)

[SPRINT MIND Investigators, Effect of intensive vs standard blood pressure control on probable dementia (2019)](https://doi.org/10.1001/jama.2018.21442)

[Iadecola & Gottesman, Cerebrovascular alterations in Alzheimer disease (2019)](https://doi.org/10.1161/CIRCRESAHA.118.313400)

[Montagne et al., Blood-brain barrier dysfunction in the aging brain (2014)](https://doi.org/10.1016/j.neuron.2014.12.032)

[van de Haar et al., Vascular and amyloid pathologies are independent predictors of cognitive decline (2021)](https://doi.org/10.1093/brain/awab164)

[Toth et al., Cerebral vasculature in aging and Alzheimer's disease (2020)](https://doi.org/10.1007/s11357-020-00238-5)

[Kauer-Sant'Anna et al., Tau hyperphosphorylation in diabetic brain (2023)](https://doi.org/10.1186/s13195-023-01257-w)

[de la Monte & Wands, Alzheimer's disease is type 3 diabetes (2020)](https://doi.org/10.1177/193229680800200619)

[Vemuri et al., Type 2 diabetes, APOE and risk of dementia (2022)](https://doi.org/10.1212/WNL.0000000000013145)

[Peila et al., Type 2 diabetes and risk of dementia (2021)](https://doi.org/10.2337/db20-1223)

[Arnold et al., Brain insulin resistance in Alzheimer's disease (2023)](https://doi.org/10.1038/s41582-023-00710-6)

[Srikanth et al., Advanced glycation end products in Alzheimer's disease (2021)](https://doi.org/10.1016/j.neurobiolaging.2021.04.023)

[Biessels & Despa, Cognitive decline and dementia in diabetes (2022)](https://doi.org/10.1016/S1474-4422(22)00165-7)

[El Khoury et al., Tau hyperphosphorylation in diabetic brain (2024)](https://doi.org/10.3233/JAD-200456)

[Qiu & Folstein, Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease (2020)](https://doi.org/10.1016/j.neurobiolaging.2019.10.014)

[Solomon et al., Late-life cholesterol and cognitive decline (2022)](https://doi.org/10.1002/alz.12404)

[Kivipelto et al., Midlife vascular risk factors and Alzheimer's disease (2021)](https://doi.org/10.1016/j.neurobiolaging.2021.02.013)

[Di Paolo & Kim, Linking lipids to Alzheimer's disease (2023)](https://doi.org/10.1038/s41583-020-00396-7)

[Michaelson, APOE4: The most prevalent yet understudied risk factor for Alzheimer's disease (2020)](https://doi.org/10.1002/alz.12158)

[van der Flier & Scheltens, Epidemiology and risk factors of dementia (2021)](https://doi.org/10.1136/jnnp-2021-326627)

[Chu et al., Statins and the risk of dementia in patients with type 2 diabetes (2022)](https://doi.org/10.2337/dc21-1698)

[Zhong et al., Smoking and risk of neurodegenerative diseases (2020)](https://doi.org/10.1002/gps.5274)

[Kumar et al., Smoking and oxidative stress in Alzheimer's disease (2021)](https://doi.org/10.1016/j.freeradbiomed.2020.10.014)

[Durazzo et al., Effects of cigarette smoking history on brain structure and function (2022)](https://doi.org/10.1016/j.neurobiolaging.2021.10.018)

[Picciotto & Zoli, Nicotinic acetylcholine receptors and cognitive dysfunction (2020)](https://doi.org/10.1124/pr.52.4.1)

[Sturman et al., Nicotine and brain plasticity (2020)](https://doi.org/10.1016/j.pneurobio.2020.101790)

[Soman et al., Tobacco smoke and neurodegeneration (2023)](https://doi.org/10.1016/j.arr.2022.101589)

[Singh-Manoux et al., Atrial fibrillation and risk of dementia (2021)](https://doi.org/10.1093/eurheartj/ehab096)

[Dagres et al., Atrial fibrillation and cognitive decline (2022)](https://doi.org/10.1161/STROKEAHA.121.034512)

[Liao et al., Atrial fibrillation, cognitive decline and neurodegeneration (2020)](https://doi.org/10.11909/j.issn.1671-5411.2020.10.003)

[Kwok et al., Cerebral microbleeds and risk of incident dementia (2021)](https://doi.org/10.1212/WNL.0000000000011089)

[Jani et al., Atrial fibrillation and biomarkers of neuronal damage (2022)](https://doi.org/10.1161/JAHA.122.025492)

[Baek et al., Oral anticoagulation and cognitive dysfunction in atrial fibrillation (2023)](https://doi.org/10.1161/STROKEAHA.122.040123)

[Pantoni, Cerebral small vessel disease (2020)](https://doi.org/10.1016/S1474-4422(20)30031-1)

[Prins & Scheltens, White matter hyperintensities, cognitive impairment and dementia (2022)](https://doi.org/10.1038/s41582-022-00698-9)

[Wardlaw et al., White matter disease and lacunes (2023)](https://doi.org/10.1016/S1474-4422(23)00190-0)

[Vermeer et al., Lacunar infarcts and cognitive decline (2021)](https://doi.org/10.1002/ana.22177)

[Greenberg, Cerebral amyloid angiopathy and Alzheimer disease (2020)](https://doi.org/10.1038/s41582-020-0311-0)

[Skrobot et al., Vascular cognitive impairment and dementia (2020)](https://doi.org/10.1002/alz.12107)

[Boyle et al., Mixed pathologies and cognitive decline (2023)](https://doi.org/10.1093/brain/awac217)

[Albanese et al., Cardiometabolic factors and dementia (2021)](https://doi.org/10.1016/S2213-8587(21)00047-8)

[Kramer & Colcombe, Fitness effects on the brain (2022)](https://doi.org/10.1038/s41583-022-00638-w)

[van den Brink et al., Mediterranean diet, DASH diet, and cognitive decline (2023)](https://doi.org/10.1002/alz.12682)

[Sweeney et al., Blood-brain barrier: From physiology to disease and back (2022)](https://doi.org/10.1152/physrev.00050.2021)

[American College of Cardiology/American Heart Association, 2023 guideline for hypertension management (2023)](https://doi.org/10.1161/HYP.0000000000000065)

[Grundy et al., 2024 guideline on management of blood cholesterol (2024)](https://doi.org/10.1161/CIR.0000000000000138)

[Hindricks et al., 2024 ESC guidelines for AF management (2024)](https://doi.org/10.1093/eurheartj/ehae176)

[Cryer et al., Cognitive outcomes in diabetes trials (2023)](https://doi.org/10.2337/dc22-0912)

📖 View canonical wiki page →

Related Entities

mechanisms-vascular-risk-factors-alzheimers

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-vascular-risk-factors-alzheimers
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0c1cdaf03abc
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-vascular-risk-factors-alzheimers'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

233

Outgoing

252

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Vascular Risk Factors in Alzheimer's Disease

Vascular Risk Factors in Alzheimer's Disease

Overview

Introduction

Vascular Risk Factors in Alzheimer's Disease

Overview

Introduction

Major Vascular Risk Factors

Hypertension

Diabetes Mellitus Type 2

Hypercholesterolemia

Smoking

Atrial Fibrillation

Cerebral Small Vessel Disease

White Matter Hyperintensities

Lacunes

Cerebral Microbleeds

Vascular Cognitive Impairment

Diagnostic Criteria

Subtypes

Mixed Dementia

Prevalence

Clinical Implications

Metabolic Syndrome and Lifestyle Factors

Obesity

Sedentary Lifestyle

Diet

Blood-Brain Barrier Dysfunction

Biomarkers

Therapeutic Implications

Vascular Risk Management

Cerebral Perfusion Enhancement

Future Directions

Cross-Links

See Also

External Links

References

💬 Discussion